MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting ...

Poster presentation to highlight the ongoing global Phase 3 ASP-1929-381 study at ASCO 2025Global patient enrollment continues, with Taiwan now actively enrolling following the U.S., and Japan ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

These abstracts summarize Versamune ® HPV (PDS0101) studies to be presented during the Head and Neck Cancer Poster Session taking place May 30-June 3, 2025, in Chicago, Illinois. Kirk Shepard, M.D., ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 ...

Awarded earlier this year, the $44M Birmingham Biotechnology Hub grant was set to support the growth of Alabama's ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc ...